Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
1) To evaluate the compliance, in terms of immunogenicity, of the influenza vaccine (split virion, inactivated) NH 2010-2011 formulation with the requirements of the Committee for Proprietary Medicinal Products (CPMP) Note for Guidance (NfG) CPMP/BWP/214/96 in both age groups 2) To describe the safety of the influenza vaccine (split virion, inactivated) NH 2010-2011 formulation in both age groups
Critère d'inclusion
- Vaccination of adults up to 60 years of age an elderly of 61 years of age and over with inactivated split-virion influenza vaccine administerd by intramuscular route